Patients with renal failure or liver disease
As expected from differences in routes of elimination, for patients with poor or no renal function, changes in terminal half-life of elimination were greatest for ofloxacin (increased from 8 to 37 h) and moderate for norfloxacin, ciprofloxacin, and enoxacin (increases ranged from 4 to 5 h to 8 to 9 h) (Table 5), while no changes occurred for pefloxacin (506). Clearance by hemodialysis was
14% or less of simultaneous plasma clearance for norfloxacin (223), ciprofloxacin
(708), ofloxacin (224), and enoxacin (546) and was 28% for pefloxacin (506).
Peritoneal dialysis also contributed minimally to clearance of ciprofloxacin (230,
691) and ofloxacin (504). For pefloxacin,